All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $239.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Dewpoint Therapeutics and Pfizer will collaborate for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $555.0 million Upfront Cash: $100.0 million
Deal Type: Collaboration November 20, 2020
Details:
Lilly will use Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy and two other undisclosed gene targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2020
Details:
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Short hairpin RNA,Gaboxadol
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Connecticut
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 23, 2020
Details:
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Transcend-peptide
Therapeutic Area: Genetic Disease Product Name: xB3
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: CHIESI USA INC
Deal Size: $141.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement June 29, 2020
Details:
The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Personalis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precision genetic therapeutics, utilizing Personalis’ advanced proprietary analytics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2020
Details:
PPMD and Duchenne UK invite proposals which are investigating ways to mitigate the immune response both in terms of pre-existing immunity and immunity induced by receiving a gene therapy dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stem cell gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rAAVrh8-HexA/HexB
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Presentations to showcase Axovant's investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-GM2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV capsid-gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
